07:11 AM EDT, 09/25/2024 (MT Newswires) -- Merck ( MRK ) said on Wednesday that its experimental combination therapy for a type of previously treated metastatic colorectal cancer did not meet the primary goal of overall survival in a phase 3 study.

The drugmaker said that at the final pre-specified analysis, its fixed-dose combination of favezelimab and Keytruda did not improve overall survival compared to standard of care.

Merck ( MRK ) said it continues to evaluate the data and plans to share the findings with the scientific community.

Price: 115.19, Change: +0.23, Percent Change: +0.20